PL2268310T3 - Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas - Google Patents

Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Info

Publication number: PL2268310T3
Authority: PL; Poland
Prior art keywords: antibody; doxorubicine; adcc; lymphomas; vincristine
Prior art date: 2008-03-25

Application number

PL09723808T

Other languages

Polish (pl)

Inventor

Charles Dumontet

Thomas Friess

Frank Herting

Christian Klein

Pablo Umana

Original Assignee

Roche Glycart Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-03-25

Filing date

2009-03-23

Publication date

2017-08-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40872445&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2268310(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-23 Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag

2017-08-31 Publication of PL2268310T3 publication Critical patent/PL2268310T3/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL09723808T 2008-03-25 2009-03-23 Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas PL2268310T3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP08005554		2008-03-25
EP08007172		2008-04-11
EP09723808.3A EP2268310B1 (en)	2008-03-25	2009-03-23	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Publications (1)

Publication Number	Publication Date
PL2268310T3 true PL2268310T3 (en)	2017-08-31

Family

ID=40872445

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL09723808T PL2268310T3 (en)	2008-03-25	2009-03-23	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin' s lymphomas

Country Status (31)

Country	Link
US (6)	US20090246197A1 (en)
EP (1)	EP2268310B1 (en)
JP (3)	JP5547709B2 (en)
KR (1)	KR101280716B1 (en)
CN (2)	CN107198772A (en)
AR (1)	AR072947A1 (en)
AU (1)	AU2009228616B2 (en)
BR (1)	BRPI0909227B8 (en)
CA (1)	CA2716884C (en)
CL (1)	CL2009000713A1 (en)
CR (1)	CR11687A (en)
CY (1)	CY1117984T1 (en)
DK (1)	DK2268310T3 (en)
ES (1)	ES2592312T3 (en)
HR (1)	HRP20161301T1 (en)
HU (1)	HUE028828T2 (en)
IL (1)	IL208018A (en)
LT (1)	LT2268310T (en)
MA (1)	MA32140B1 (en)
MX (1)	MX2010009647A (en)
MY (1)	MY163544A (en)
NZ (1)	NZ587284A (en)
PE (1)	PE20091821A1 (en)
PL (1)	PL2268310T3 (en)
PT (1)	PT2268310T (en)
RS (1)	RS55258B1 (en)
RU (1)	RU2589704C2 (en)
SI (1)	SI2268310T1 (en)
TW (1)	TWI500624B (en)
WO (1)	WO2009118142A1 (en)
ZA (1)	ZA201006190B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2961563B2 (en)	1991-01-29	1999-10-12	株式会社トーキン	Method of manufacturing magnetic wire for pulse generation
ME01775B (en)	2003-11-05	2011-02-28	Glycart Biotechnology Ag	Cd20 antibodies with increased fc receptor binding affinity and effector function
ES2592312T3 (en) *	2008-03-25	2016-11-29	Roche Glycart Ag	Use of an anti-CD20 type II antibody with increased antibody-dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicin for the treatment of non-Hodgkin lymphomas
TW201438738A (en)	2008-09-16	2014-10-16	Genentech Inc	Method for treating progressive multiple sclerosis
AR078161A1 (en)	2009-09-11	2011-10-19	Hoffmann La Roche	VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD
NZ604040A (en)	2010-06-03	2015-02-27	Pharmacyclics Inc	The use of inhibitors of bruton’s tyrosine kinase (btk)
RU2013131444A (en) *	2010-12-16	2015-01-27	Рош Гликарт Аг	COMBINED THERAPY BY AFUCOSYLED ANTIBODY TO CD20 AND MDM2 INHIBITOR
EP2771010A4 (en) *	2011-10-19	2015-04-01	Pharmacyclics Inc	USE OF INHIBITORS OF BRUTON TYROSINE KINASE (BTK)
US20130302274A1 (en) *	2011-11-25	2013-11-14	Roche Glycart Ag	Combination therapy
KR20150032340A (en)	2012-07-24	2015-03-25	파마시클릭스, 인코포레이티드	Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
KR20160089532A (en) *	2013-12-17	2016-07-27	제넨테크, 인크.	Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody
US9732154B2 (en)	2014-02-28	2017-08-15	Janssen Biotech, Inc.	Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) *	2014-02-28	2017-03-28	Janssen Biotech, Inc.	Combination therapies with anti-CD38 antibodies
MY192918A (en)	2014-09-09	2022-09-15	Janssen Biotech Inc	Combination therapies with anti-cd38 antibodies
EP3227338A4 (en)	2014-12-04	2018-05-16	Janssen Biotech, Inc.	Anti-cd38 antibodies for treatment of acute myeloid leukemia
IL254817B2 (en)	2015-04-08	2023-12-01	Novartis Ag	CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cells
CR20170526A (en)	2015-05-20	2018-04-03	Janssen Biotech Inc	ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF LIGHT CHAIN AMYLOIDOSIS and OTHER POSITIVE HEMATOLOGICAL MALIGNAL DISEASES FOR CD38
MY192978A (en)	2015-06-22	2022-09-20	Janssen Biotech Inc	Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors
US20170044265A1 (en)	2015-06-24	2017-02-16	Janssen Biotech, Inc.	Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
PL3827845T3 (en)	2015-11-03	2022-07-11	Janssen Biotech, Inc.	Subcutaneous formulations of anti-cd38 antibodies and their uses
US10781261B2 (en)	2015-11-03	2020-09-22	Janssen Biotech, Inc.	Subcutaneous formulations of anti-CD38 antibodies and their uses
EP3386549A4 (en) *	2015-12-10	2019-08-07	City of Hope	ANTIBODIES COUPLED WITH CYANINE WITH CELL PENETRATION
EP3523331A1 (en)	2016-10-07	2019-08-14	Novartis AG	Chimeric antigen receptors for the treatment of cancer
EP3551047A1 (en)	2016-12-07	2019-10-16	Progenity, Inc.	Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en)	2017-03-30	2021-05-13	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
CA3079242A1 (en)	2017-10-31	2019-05-09	Janssen Biotech, Inc.	Methods of treating high risk multiple myeloma
WO2019246317A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease or condition in a tissue originating from the endoderm
US20230041197A1 (en)	2018-06-20	2023-02-09	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN116726362A (en)	2018-11-19	2023-09-12	比奥拉治疗股份有限公司	Methods and devices for treating diseases with biologic therapeutic agents
US20240050562A1 (en) *	2019-10-04	2024-02-15	Chugai Seiyaku Kabushiki Kaisha	Inhibitor of cell proliferation in obinutuzumab resistant cd20-positive cancer, and medicinal composition, medicine, production, method for inhibiting cell proliferation, therapeutic method, type ii anti-cd20 antibody, compounds, combination of same, enhancer and inducer, each relating thereto
CN115666704B (en)	2019-12-13	2025-09-26	比特比德科有限责任公司	Ingestible device for delivering therapeutic agents to the gastrointestinal tract

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en)	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US5736137A (en) *	1992-11-13	1998-04-07	Idec Pharmaceuticals Corporation	Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
JP4334141B2 (en) *	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	Engineering glycosylation of antibodies to improve antibody-dependent cytotoxicity
RU2306952C2 (en) *	2001-01-31	2007-09-27	Байоджен Айдек Инк.	Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies
WO2004035607A2 (en)	2002-10-17	2004-04-29	Genmab A/S	Human monoclonal antibodies against cd20
PT1572744E (en) *	2002-12-16	2010-09-07	Genentech Inc	Immunoglobulin variants and uses thereof
ME01775B (en) *	2003-11-05	2011-02-28	Glycart Biotechnology Ag	Cd20 antibodies with increased fc receptor binding affinity and effector function
DOP2006000029A (en) *	2005-02-07	2006-08-15	Genentech Inc	ANTIBODY VARIANTS AND USES THEREOF. (VARIATIONS OF AN ANTIBODY AND USES OF THE SAME)
US20110129412A1 (en) *	2005-06-02	2011-06-02	Astrazeneca Ab	Antibodies Directed to CD20 and Uses Thereof
WO2007031875A2 (en) *	2005-08-26	2007-03-22	Glycart Biotechnology Ag	Modified antigen binding molecules with altered cell signaling activity
JP5209723B2 (en) *	2007-09-05	2013-06-12	エフ．ホフマン−ラロシュアーゲー	Combination Therapy with Type I and Type II Anti-CD20 Antibodies
ES2592312T3 (en) *	2008-03-25	2016-11-29	Roche Glycart Ag	Use of an anti-CD20 type II antibody with increased antibody-dependent cellular cytotoxicity (ADCC) in combination with cyclophosphamide, vincristine and doxorubicin for the treatment of non-Hodgkin lymphomas

2009
- 2009-03-23 ES ES09723808.3T patent/ES2592312T3/en active Active
- 2009-03-23 TW TW098109412A patent/TWI500624B/en active
- 2009-03-23 PL PL09723808T patent/PL2268310T3/en unknown
- 2009-03-23 WO PCT/EP2009/002111 patent/WO2009118142A1/en not_active Ceased
- 2009-03-23 CA CA2716884A patent/CA2716884C/en active Active
- 2009-03-23 MX MX2010009647A patent/MX2010009647A/en active IP Right Grant
- 2009-03-23 AU AU2009228616A patent/AU2009228616B2/en active Active
- 2009-03-23 JP JP2011501133A patent/JP5547709B2/en active Active
- 2009-03-23 SI SI200931530A patent/SI2268310T1/en unknown
- 2009-03-23 NZ NZ587284A patent/NZ587284A/en unknown
- 2009-03-23 DK DK09723808.3T patent/DK2268310T3/en active
- 2009-03-23 HU HUE09723808A patent/HUE028828T2/en unknown
- 2009-03-23 KR KR1020107021332A patent/KR101280716B1/en active Active
- 2009-03-23 RS RS20160864A patent/RS55258B1/en unknown
- 2009-03-23 PT PT97238083T patent/PT2268310T/en unknown
- 2009-03-23 AR ARP090101035A patent/AR072947A1/en unknown
- 2009-03-23 MY MYPI2010004461A patent/MY163544A/en unknown
- 2009-03-23 US US12/408,746 patent/US20090246197A1/en not_active Abandoned
- 2009-03-23 LT LTEP09723808.3T patent/LT2268310T/en unknown
- 2009-03-23 BR BRPI0909227A patent/BRPI0909227B8/en active IP Right Grant
- 2009-03-23 RU RU2010143454/15A patent/RU2589704C2/en active
- 2009-03-23 CN CN201611215290.7A patent/CN107198772A/en active Pending
- 2009-03-23 HR HRP20161301TT patent/HRP20161301T1/en unknown
- 2009-03-23 CL CL2009000713A patent/CL2009000713A1/en unknown
- 2009-03-23 CN CN2009801101810A patent/CN101983071A/en active Pending
- 2009-03-23 EP EP09723808.3A patent/EP2268310B1/en active Active
- 2009-03-24 PE PE2009000437A patent/PE20091821A1/en not_active Application Discontinuation
2010
- 2010-05-10 US US12/777,141 patent/US20100310581A1/en not_active Abandoned
- 2010-08-30 ZA ZA2010/06190A patent/ZA201006190B/en unknown
- 2010-09-03 MA MA33145A patent/MA32140B1/en unknown
- 2010-09-06 IL IL208018A patent/IL208018A/en active IP Right Grant
- 2010-09-23 CR CR11687A patent/CR11687A/en unknown
2011
- 2011-03-07 US US13/042,305 patent/US20110177067A1/en not_active Abandoned
- 2011-10-28 US US13/284,415 patent/US20120301459A1/en not_active Abandoned
2013
- 2013-03-14 US US13/829,409 patent/US20140065134A1/en not_active Abandoned
2014
- 2014-01-24 JP JP2014011332A patent/JP5912142B2/en active Active
- 2014-06-05 US US14/297,478 patent/US20160000911A1/en not_active Abandoned
2016
- 2016-03-18 JP JP2016055096A patent/JP6154039B2/en active Active
- 2016-09-07 CY CY20161100889T patent/CY1117984T1/en unknown

Also Published As

Publication number	Publication date
JP5547709B2 (en)	2014-07-16
HRP20161301T1 (en)	2016-11-18
CN101983071A (en)	2011-03-02
ES2592312T3 (en)	2016-11-29
CY1117984T1 (en)	2017-05-17
KR101280716B1 (en)	2013-07-01
JP2014101370A (en)	2014-06-05
RS55258B1 (en)	2017-02-28
JP5912142B2 (en)	2016-04-27
SI2268310T1 (en)	2016-11-30
NZ587284A (en)	2012-05-25
CA2716884C (en)	2017-10-03
PE20091821A1 (en)	2009-11-25
MA32140B1 (en)	2011-03-01
KR20100121525A (en)	2010-11-17
IL208018A0 (en)	2010-12-30
JP2011515428A (en)	2011-05-19
BRPI0909227B1 (en)	2020-11-24
US20160000911A1 (en)	2016-01-07
US20120301459A1 (en)	2012-11-29
CA2716884A1 (en)	2009-10-01
HUE028828T2 (en)	2017-01-30
BRPI0909227B8 (en)	2021-05-25
WO2009118142A1 (en)	2009-10-01
JP6154039B2 (en)	2017-06-28
EP2268310B1 (en)	2016-07-20
AU2009228616A1 (en)	2009-10-01
RU2589704C2 (en)	2016-07-10
PT2268310T (en)	2016-08-23
TW200951141A (en)	2009-12-16
DK2268310T3 (en)	2016-08-15
US20090246197A1 (en)	2009-10-01
MY163544A (en)	2017-09-29
AU2009228616B2 (en)	2014-07-24
EP2268310A1 (en)	2011-01-05
CR11687A (en)	2011-01-10
LT2268310T (en)	2016-09-26
RU2010143454A (en)	2012-05-10
US20100310581A1 (en)	2010-12-09
TWI500624B (en)	2015-09-21
CL2009000713A1 (en)	2010-04-09
US20140065134A1 (en)	2014-03-06
AR072947A1 (en)	2010-10-06
BRPI0909227A2 (en)	2015-12-01
ZA201006190B (en)	2018-11-28
CN107198772A (en)	2017-09-26
JP2016121183A (en)	2016-07-07
US20110177067A1 (en)	2011-07-21
IL208018A (en)	2017-12-31
MX2010009647A (en)	2010-09-28

Publication	Publication Date	Title
IL208018A0 (en)	2010-12-30	Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
ZA201002773B (en)	2011-10-26	Porcine dc-sign,icam-3 and lsectin and uses thereof
IL254498B (en)	2020-02-27	Peptidomimetic macrocycle composition for use in treating disease
EP1772126A4 (en)	2010-11-24	Apparatus for producing absorbing material, absorbing material and absorbent article
EP2177524A4 (en)	2011-12-14	Heterocyclic compound, ultraviolet ray absorbent, and composition comprising the ultraviolet ray absorbent
IL200905A0 (en)	2010-05-17	Compounds and compositions comprising the same for use in treating hepatitis c
ZA200802274B (en)	2009-01-28	Absorbent article with improved garment-like character
EP2039817A4 (en)	2011-05-25	Absorbent, multilayered absorbent, and absorbent article
EP2367665A4 (en)	2013-12-11	Composition and method for treating wood-based material and wood-based material treated with the composition
EP2246402A4 (en)	2011-02-16	Resin composition, laminate using the same, and molded body using the laminate
EP2371904A4 (en)	2012-10-03	Near-infrared-ray absorbing material containing cyanine compound, and cyanine compound
IL205939A (en)	2014-07-31	Compounds for use in treating lysosomal disorders
EP1868435A4 (en)	2009-04-01	Combinations, methods and compositions for treating cancer
ZA200903771B (en)	2010-08-25	Carbamate compounds for use in treating depression
EP2213386A4 (en)	2013-12-11	Method for washing soil containing cyanogen compound, and microorganism for use in the washing method
EP2085061A4 (en)	2013-08-28	Process for producing absorbent article, and absorbent article
PL2110241T3 (en)	2014-12-31	Compound material, in particular for highly extendable and semi-elastic closing elements on nappies
GB2450812B (en)	2010-09-15	Compound, ink, process and use
EP2007838A4 (en)	2010-12-08	Near-infrared absorbing material
GB0603062D0 (en)	2006-03-29	Method, composition and articles
ZA200902612B (en)	2009-12-30	Rubber composition for belt and rubber belt
GB0612029D0 (en)	2006-07-26	Compound, ink, process and use
EP2150243A4 (en)	2013-08-21	Compositions and methods for enhancing active agent absorption
GB0620089D0 (en)	2006-11-22	Process, composition and ink
GB0922009D0 (en)	2010-02-03	Compound, ink, process and use